3 Stocks I Saw on T...
Health Care: Drugs
InterMune Inc. (ITMN: NASDAQ)
$15.99 -0.01 | -0.06%
02/06/12 - 04:00 PM ET
1.83M / 2.24M
Vol / Avg. Vol:15.87 / 16.00
Open / Prev. Close:15.82 - 16.48
Today's Range:10.67 - 51.71
52 Wk Range:26.90%
Performance YTD:TheStreet Rating:
Portfolios with ITMN
- Portfolio NameUser Type
- Userskyisfalling
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Contributor5 Biotech Stocks for 2012
- ProD.E. Shaw
- Contributor3 Health Care Stocks That C...
- Userdec28/10
- ProQVT Financial
- UserSUPRATRADE HOT STOCKS (BUY ...
- Contributor10 Biotech Stocks Facing FD...
Latest ITMN Headlines from TheStreet
- 8 Stocks Rising on Huge Volume 01.05.12 | 02:01 pm
- Dendreon: Provenge Q4 Sales Beat 01.05.12 | 10:01 am
- Biotech 2012 Kickoff Party: Investor Preview 01.04.12 | 11:01 am
- InterMune Stock Hits New 52-Week Low (ITMN) 12.16.11 | 11:12 am
- InterMune Stock Falls On Unusually High Volume (ITMN) 12.15.11 | 11:12 am
- 5 Stocks Setting Up to Break Out 12.13.11 | 12:12 pm
- 5 Biotech Stocks for 2012 12.09.11 | 09:12 am
- 3 Health Care Stocks That Could Gain 50% or More 11.03.11 | 01:11 pm
- InterMune Inc. (ITMN): Today's Featured Health Care Loser 10.05.11 | 04:10 pm
- InterMune Stock Falls On Unusually High Volume (ITMN) 09.13.11 | 04:09 pm
Press Releases for ITMN
- InterMune To Release Fourth Quarter And Full Year Financial Results On February 9 - PR Newswire 02.02.12 | 04:02 pm
- InterMune To Present At J. P. Morgan Healthcare Conference - PR Newswire 01.05.12 | 04:01 pm
- InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue And Other Recent Business Highlights - PR Newswire 01.05.12 | 07:01 am
- InterMune To Report Unaudited Fourth Quarter Esbriet® Revenue And Business Update On January 5 - PR Newswire 01.04.12 | 08:01 am
- IQWIG Publishes Early Benefit Assessment For Pirfenidone - PR Newswire 12.15.11 | 07:12 pm
- InterMune To Present At Oppenheimer & Co. 22nd Annual Healthcare Conference On Dec. 14 - PR Newswire 12.07.11 | 08:12 am
- InterMune Appoints Angus C. Russell To Board Of Directors - PR Newswire 10.31.11 | 04:10 pm
- InterMune To Release Third Quarter Financial Results On November 3 - PR Newswire 10.27.11 | 08:10 am
- New Data Demonstrate Longer-Term Safety Profile Of Esbriet® - PR Newswire 09.26.11 | 06:09 am
- InterMune Announces Pricing Of Concurrent Public Offerings Of 4,000,000 Shares Of Common Stock And $135 Million Principal Amount Of Convertible Senior Notes - PR Newswire 09.13.11 | 08:09 pm
Partner Headlines for ITMN
- The Zacks Analyst Blog Highlights: Gilead Sciences, Pharmasset, Nasdaq Biotechnology ETF, InterMune and Dendreon - Press Releases - Zacks 11.22.11 | 09:11 am
- Stock Picks From Nobel Prize Winner's Hutchin Hill Capital - Seeking Alpha 11.04.11 | 10:11 pm
- 3 Healthcare Stocks To Consider - Seeking Alpha 11.03.11 | 08:11 am
- 10 Overvalued Healthcare Stocks - Seeking Alpha 10.25.11 | 08:10 am
- ITMN's Esbriet Safe Long Term - Analyst Blog - Zacks 09.30.11 | 03:09 pm
- Company News for September 14, 2011 - Corporate Summary - Zacks 09.14.11 | 10:09 am
- UPDATE: InterMune Announces Proposed Concurrent Public Offerings, 4M Shares of Common Stock and $100M Convertible Debt Senior Notes - Benzinga 09.12.11 | 04:09 pm
- 10 Stocks With Bullish Momentum Backed By Strong Top Line Growth - Seeking Alpha 08.24.11 | 08:08 am
- InterMune Loss Rise, Costs Flare Up - Analyst Blog - Zacks 08.05.11 | 04:08 pm
- 3 Biotech Stocks Predictive Analysts Expect to Outperform - Seeking Alpha 07.24.11 | 08:07 am
